|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Mutations in the Fas Antigen in Patients With Multiple Myeloma
Terry H. Landowski,
Ning Qu,
Ibrahim Buyuksal,
Jeffrey S. Painter, and
William S. Dalton
From the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa; and the Arizona Cancer Center, University of Arizona, Tucson.
Programmed cell death, or apoptosis, is well documented as a physiological means of eliminating activated lymphocytes and maintaining immune homeostasis. Apoptosis has also been implicated in the targeting of tumor cells by cytotoxic T lymphocytes and natural killer cells. One of the two primary mechanisms used in cell-mediated cytotoxicity is the Fas/FasLigand system. Activated or transformed cells expressing the Fas antigen on their surface are susceptible to killing by immune effector cells that express the Fas ligand. Many neoplastic cells, including those derived from patients with multiple myeloma, express Fas antigen on their surface, but do not undergo apoptosis in response to antigen crosslinking. One possibility for the lack of Fas-mediated apoptosis includes mutations in the Fas antigen. Loss of function mutations in the Fas antigen have been associated with congenital autoimmune disease in humans, and have been defined as the genetic defect the in lpr mice. Mutations in the Fas antigen have not been previously described in cancer patients. In this study, we show that mutations occur in the Fas antigen which may cause loss of function and contribute to the pathogenesis of the neoplastic disease, multiple myeloma. Using reverse transcriptase-polymerase chain reaction (RT-PCR), single-stranded conformation polymorphism (SSCP) analysis, and DNA sequencing, we examined the cDNA structure of the Fas antigen in 54 bone marrow (BM) specimens obtained from myeloma patients. Six patient specimens (11%) did not express detectable levels of Fas antigen mRNA. Of the 48 BM specimens which did express Fas antigen, 5 (10%) displayed point mutations. All of the mutations identified were located in the cytoplasmic region of the Fas antigen known to be involved in transduction of an apoptotic signal. Two separate individuals demonstrated an identical mutation at a site previously shown to be mutated in the congenital autoimmune syndrome, ALPS. One patient exhibited a point mutation at a site only two amino acids removed from the documented lesion of the lprcg mouse. Although the functional status of these point mutations remains to be determined, we propose that Fas antigen mutations may contribute to the pathogenesis and progression of myeloma in some patients.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4266-4270
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy Jr, J. Epstein, et al.
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
Blood,
September 1, 2007;
110(5):
1587 - 1594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Duquette, M. D. Huber, and N. Maizels
G-Rich Proto-Oncogenes Are Targeted for Genomic Instability in B-Cell Lymphomas
Cancer Res.,
March 15, 2007;
67(6):
2586 - 2594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Hyer, T. Samuel, and J. C. Reed
The FLIP-Side of Fas Signaling
Clin. Cancer Res.,
October 15, 2006;
12(20):
5929 - 5931.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hua, S. Hautaniemi, R. Yokoo, and D. A Lauffenburger
Integrated mechanistic and data-driven modelling for multivariate analysis of signalling pathways
J R Soc Interface,
August 22, 2006;
3(9):
515 - 526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Ghobrial, T. E. Witzig, and A. A. Adjei
Targeting Apoptosis Pathways in Cancer Therapy
CA Cancer J Clin,
May 1, 2005;
55(3):
178 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya
Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes
Cancer Res.,
September 15, 2004;
64(18):
6775 - 6782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hiatt, D. A. Ingram, H. Huddleston, D. F. Spandau, R. Kapur, and D. W. Clapp
Loss of the Nf1 Tumor Suppressor Gene Decreases Fas Antigen Expression in Myeloid Cells
Am. J. Pathol.,
April 1, 2004;
164(4):
1471 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Evens, S. Prachand, B. Shi, M. Paniaqua, L. I. Gordon, and R. B. Gartenhaus
Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent
Clin. Cancer Res.,
February 15, 2004;
10(4):
1481 - 1491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. N. Ivanov, P. L. Bergami, G. Maulit, T.-A. Sato, D. Sassoon, and Z.'e. Ronai
FAP-1 Association with Fas (Apo-1) Inhibits Fas Expression on the Cell Surface
Mol. Cell. Biol.,
May 15, 2003;
23(10):
3623 - 3635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Gordon, C. M. Kanegai, J. R. Doerr, and R. Wall
Somatic hypermutation of the B cell receptor genes B29 (Igbeta , CD79b) and mb1 (Igalpha , CD79a)
PNAS,
April 1, 2003;
100(7):
4126 - 4131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood,
February 15, 2003;
101(4):
1220 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Shen, A. C. T. Liang, L. Lu, W. Y. Au, Y.-L. Kwong, R. H. S. Liang, and G. Srivastava
Frequent Deletion of Fas Gene Sequences Encoding Death and Transmembrane Domains in Nasal Natural Killer/T-Cell Lymphoma
Am. J. Pathol.,
December 1, 2002;
161(6):
2123 - 2131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-o. Lee, J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson
TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site
J. Immunol.,
November 1, 2002;
169(9):
4739 - 4744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takayama, T. Takakuwa, Y. Tsujimoto, Y. Tani, N. Nonomura, A. Okuyama, S. Nagata, and K. Aozasa
Frequent Fas Gene Mutations in Testicular Germ Cell Tumors
Am. J. Pathol.,
August 1, 2002;
161(2):
635 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S. H. Lim
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Blood,
July 18, 2002;
100(3):
961 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol.,
June 1, 2002;
71(6):
907 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, and Q. Yi
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
Blood,
May 1, 2002;
99(9):
3280 - 3285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Shain, T. H. Landowski, and W. S. Dalton
Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines
J. Immunol.,
March 1, 2002;
168(5):
2544 - 2553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Straus, E. S. Jaffe, J. M. Puck, J. K. Dale, K. B. Elkon, A. Rosen-Wolff, A. M. J. Peters, M. C. Sneller, C. W. Hallahan, J. Wang, et al.
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
Blood,
July 1, 2001;
98(1):
194 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Wen, B. Barlogie, and Q. Yi
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells
Blood,
March 15, 2001;
97(6):
1750 - 1755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takakuwa, Z. Dong, H. Takayama, F. Matsuzuka, S. Nagata, and K. Aozasa
Frequent Mutations of Fas Gene in Thyroid Lymphoma
Cancer Res.,
February 1, 2001;
61(4):
1382 - 1385.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Muschen, D. Re, B. Jungnickel, V. Diehl, K. Rajewsky, and R. Kuppers
Somatic Mutation of the Cd95 Gene in Human B Cells as a Side-Effect of the Germinal Center Reaction
J. Exp. Med.,
December 18, 2000;
192(12):
1833 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Chang and X. Yang
Proteases for Cell Suicide: Functions and Regulation of Caspases
Microbiol. Mol. Biol. Rev.,
December 1, 2000;
64(4):
821 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Müschen, D. Re, A. Bräuninger, J. Wolf, M.-L. Hansmann, V. Diehl, R. Küppers, and K. Rajewsky
Somatic Mutations of the CD95 Gene in Hodgkin and Reed-Sternberg Cells
Cancer Res.,
October 1, 2000;
60(20):
5640 - 5643.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. M. Mueller and D. W. Scott
Distinct Molecular Mechanisms of Fas Resistance in Murine B Lymphoma Cells
J. Immunol.,
August 15, 2000;
165(4):
1854 - 1862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Pinkoski, T. Brunner, D. R. Green, and T. Lin
Fas and Fas ligand in gut and liver
Am J Physiol Gastrointest Liver Physiol,
March 1, 2000;
278(3):
G354 - G366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Reed
Dysregulation of Apoptosis in Cancer
J. Clin. Oncol.,
September 1, 1999;
17(9):
2941 - 2941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Lee, M. S. Shin, W. S. Park, S. Y. Kim, S. M. Dong, J. H. Pi, H. K. Lee, H. S. Kim, J. J. Jang, C. S. Kim, et al.
Alterations of Fas (APO-1/CD95) Gene in Transitional Cell Carcinomas of Urinary Bladder
Cancer Res.,
July 1, 1999;
59(13):
3068 - 3072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Shin, W. S. Park, S. Y. Kim, H. S. Kim, S. J. Kang, K. Y. Song, J. Y. Park, S. M. Dong, J. H. Pi, R. R. Oh, et al.
Alterations of Fas (Apo-1/CD95) Gene in Cutaneous Malignant Melanoma
Am. J. Pathol.,
June 1, 1999;
154(6):
1785 - 1791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Maeda, Y. Yamada, R. Moriuchi, K. Sugahara, K. Tsuruda, T. Joh, S. Atogami, K. Tsukasaki, M. Tomonaga, and S. Kamihira
Fas Gene Mutation in the Progression of Adult T Cell Leukemia
J. Exp. Med.,
April 5, 1999;
189(7):
1063 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Chang, X. Yang, and D. Baltimore
Dissecting Fas signaling with an altered-specificity death-domain mutant: Requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation
PNAS,
February 16, 1999;
96(4):
1252 - 1256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lamy, J. H. Liu, T. H. Landowski, W. S. Dalton, and T. P. Loughran Jr
Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia
Blood,
December 15, 1998;
92(12):
4771 - 4777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. R. Rifkin, P. L. Channavajhala, H. L.B. Kiefer, A. J. Carmack, E. Landesman-Bollag, B. C. Beaudette, B. Jersky, D. J. Salant, S.-T. Ju, A. Marshak-Rothstein, et al.
Acceleration of lpr Lymphoproliferative and Autoimmune Disease by Transgenic Protein Kinase CK2{alpha}
J. Immunol.,
November 15, 1998;
161(10):
5164 - 5170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Gronbak, P. t. Straten, E. Ralfkiaer, V. Ahrenkiel, M. K. Andersen, N. E. Hansen, J. Zeuthen, K. Hou-Jensen, and P. Guldberg
Somatic Fas Mutations in Non-Hodgkin's Lymphoma: Association With Extranodal Disease and Autoimmunity
Blood,
November 1, 1998;
92(9):
3018 - 3024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Davidson, T. Giese, and T. N. Fredrickson
Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas-Fas Ligand Interactions
J. Exp. Med.,
June 1, 1998;
187(11):
1825 - 1838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tamiya, K.-i. Etoh, H. Suzushima, K. Takatsuki, and M. Matsuoka
Mutation of CD95 (Fas/Apo-1) Gene in Adult T-Cell Leukemia Cells
Blood,
May 15, 1998;
91(10):
3935 - 3942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
